Northern Trust Corp. (NTRS) Falls 2.98% for January 04

Equities Staff |

One of the S&P 500’s big losers for Monday January 04 was Northern Trust Corp. (NTRS). The company’s stock fell 2.98% to $69.94 on volume of 1.23 million shares.

The stock opened the day at 70.29 and traded between a low of $69.66 and a high of $70.90. The stock finished the day down $2.15 per share. Northern Trust Corp. has an average daily volume of 1.35 million and a total float of 231.22 million shares. The 50-day SMA for Northern Trust Corp. is $72.60 and its 200-day SMA is $72.50. The high for the stock over the last 52 weeks is $79.25 and the low is $61.10.

Northern Trust Corp is a financial holding company that provides asset servicing, fund administration, asset management, fiduciary and banking solutions for corporations, institutions, families and individuals.

Northern Trust Corp. is centered in Chicago, IL, and has 15,400 employees. Today’s trading day leaves the company with a market cap of $16.17 billionwith a P/E Ratio of 18.1. The company has a P/S ratio of 4.56, P/B ratio of 1.93, and a -280.1.

For a complete fundamental analysis analysis of Northern Trust Corp., check out Equities.com’s Stock Valuation Analysis report for NTRS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

Snapwire

A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.